{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:48:02Z","timestamp":1791110882272,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1245\/s10434-023-13463-x","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T22:01:59Z","timestamp":1682114519000},"page":"4459-4470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of Primary Tumor Location and Genomic Alterations on Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Colorectal Peritoneal Metastases"],"prefix":"10.1245","volume":"30","author":[{"given":"Ahmed B.","family":"Hamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongli","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Derby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Ongchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Pingpank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reetesh","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aatur","family":"Singhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon A.","family":"Choudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"issue":"12","key":"13463_CR1","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 2016;17(12):1709\u201319.","journal-title":"Lancet Oncol"},{"issue":"2","key":"13463_CR2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Quenet","year":"2021","unstructured":"Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, Marchal F, Loi V, Meeus P, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366.","journal-title":"Lancet Oncol"},{"issue":"20","key":"13463_CR3","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737\u201343.","journal-title":"J Clin Oncol"},{"issue":"1","key":"13463_CR4","first-page":"45","volume":"7","author":"MD Goodman","year":"2016","unstructured":"Goodman MD, McPartland S, Detelich D, Saif MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol. 2016;7(1):45\u201357.","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"13463_CR5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/ejhpharm-2016-000877","volume":"23","author":"P Mistry","year":"2016","unstructured":"Mistry P, Mohamed F, Dayal S, Cecil TD, Moran BJ. Cytoreductive surgery with intraperitoneal chemotherapy in the management of peritoneal surface malignancy: a pharmacist\u2019s perspective. Eur J Hosp Pharm. 2016;23(4):233\u20138.","journal-title":"Eur J Hosp Pharm"},{"issue":"2","key":"13463_CR6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1515\/pp-2017-0004","volume":"2","author":"M Steuperaert","year":"2017","unstructured":"Steuperaert M, Debbaut C, Segers P, Ceelen W. Modelling drug transport during intraperitoneal chemotherapy. Pleura Peritoneum. 2017;2(2):73\u201383.","journal-title":"Pleura Peritoneum"},{"key":"13463_CR7","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.2147\/CMAR.S277912","volume":"13","author":"GA Simkens","year":"2021","unstructured":"Simkens GA, Wintjens A, Rovers KP, Nienhuijs SW, de Hingh IH. effective strategies to predict survival of colorectal peritoneal metastases patients eligible for cytoreductive surgery and HIPEC. Cancer Manag Res. 2021;13:5239\u201349.","journal-title":"Cancer Manag Res"},{"key":"13463_CR8","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1038\/s41467-022-32198-z","volume":"13","author":"KJ Lenos","year":"2022","unstructured":"Lenos KJ, Bach S, Ferreira Moreno L, et al. Molecular characterization of colorectal cancer related peritoneal metastatic disease. Nat Commun. 2022;13:4443.","journal-title":"Nat Commun"},{"key":"13463_CR9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.21037\/ales.2019.07.10","volume":"4","author":"XD Dong","year":"2019","unstructured":"Dong XD. Right sided colon cancer and peritoneal carcinomatosis. Ann Laparosc Endosc Surg. 2019;4:72.","journal-title":"Ann Laparosc Endosc Surg"},{"issue":"3","key":"13463_CR10","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/cam4.2747","volume":"9","author":"LC Bylsma","year":"2020","unstructured":"Bylsma LC, Gillezeau C, Garawin TA, et al. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: a systematic review and meta-analysis. Cancer Med. 2020;9(3):1044\u201357.","journal-title":"Cancer Med"},{"issue":"4","key":"13463_CR11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.14740\/gr1062w","volume":"11","author":"B Baran","year":"2018","unstructured":"Baran B, Mert Ozupek N, Yerli Tetik N, Acar E, Bekcioglu O, Baskin Y. Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterol Res. 2018;11(4):264\u201373.","journal-title":"Gastroenterol Res"},{"issue":"3","key":"13463_CR12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.hpb.2019.10.003","volume":"22","author":"FE Buisman","year":"2020","unstructured":"Buisman FE, Galjart B, Buettner S, Groot Koerkamp B, Gr\u00fcnhagen DJ, Verhoef C. Primary tumor location and the prognosis of patients after local treatment of colorectal liver metastases: a systematic review and meta-analysis. HPB. 2020;22(3):351\u20137.","journal-title":"HPB"},{"issue":"4","key":"13463_CR13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000505128","volume":"98","author":"K Matsuda","year":"2020","unstructured":"Matsuda K, Tamura K, Iwamoto H, et al. Tumor sidedness is associated with survival in patients with synchronous colorectal peritoneal carcinomatosis. Oncology. 2020;98(4):230\u20136.","journal-title":"Oncology"},{"issue":"7","key":"13463_CR14","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1245\/s10434-019-07373-0","volume":"26","author":"NV Kotha","year":"2019","unstructured":"Kotha NV, Baumgartner JM, Veerapong J, et al. Primary tumor sidedness is predictive of survival in colon cancer patients treated with cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy: a US HIPEC collaborative study. Ann Surg Oncol. 2019;26(7):2234\u201340.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"13463_CR15","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1245\/s10434-019-07255-5","volume":"26","author":"KJ Kelly","year":"2019","unstructured":"Kelly KJ, Alsayadnasser M, Vaida F, et al. Does primary tumor side matter in patients with metastatic colon cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol. 2019;26(5):1421\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"13463_CR16","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1002\/cam4.3243","volume":"9","author":"NL de Boer","year":"2020","unstructured":"de Boer NL, Rovers K, Burger JWA, et al. A population-based study on the prognostic impact of primary tumor sidedness in patients with peritoneal metastases from colon cancer. Cancer Med. 2020;9(16):5851\u20139.","journal-title":"Cancer Med"},{"issue":"11","key":"13463_CR17","doi-asserted-by":"crossref","first-page":"e78709","DOI":"10.1371\/journal.pone.0078709","volume":"8","author":"YC Lee","year":"2013","unstructured":"Lee YC, Lee YL, Chuang JP, Lee JC. Differences in survival between colon and rectal cancer from seer data. PLoS One. 2013;8(11):e78709.","journal-title":"PLoS One."},{"issue":"2","key":"13463_CR18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/DCR.0000000000002228","volume":"66","author":"Y Takamizawa","year":"2023","unstructured":"Takamizawa Y, Shida D, Horie T, et al. Prognostic role for primary tumor location in patients with colorectal liver metastases: a comparison of right-sided colon, left-sided colon, and rectum. Dis Colon Rectum. 2023;66(2):233.","journal-title":"Dis Colon Rectum"},{"key":"13463_CR19","first-page":"127","volume":"90","author":"G Gallo","year":"2019","unstructured":"Gallo G, Sena G, Vescio G, et al. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer: a systematic review. Ann Ital Chir. 2019;90:127\u201337.","journal-title":"Ann Ital Chir"},{"issue":"12","key":"13463_CR20","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.21873\/anticanres.13857","volume":"39","author":"F Petrelli","year":"2019","unstructured":"Petrelli F, Ghidini M, Cabiddu M, et al. Microsatellite instability and survival in stage II colorectal cancer: a systematic review and meta-analysis. Anticancer Res. 2019;39(12):6431\u201341.","journal-title":"Anticancer Res"},{"issue":"9","key":"13463_CR21","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/annonc\/mdz208","volume":"30","author":"J Taieb","year":"2019","unstructured":"Taieb J, Shi Q, Pederson L, et al. Prognosis of microsatellite instability and\/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann Oncol. 2019;30(9):1466\u201371.","journal-title":"Ann Oncol"},{"issue":"4","key":"13463_CR22","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41416-020-01169-w","volume":"124","author":"AA J\u00e1come","year":"2021","unstructured":"J\u00e1come AA, Vreeland TJ, Johnson B, et al. The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients. Br J Cancer. 2021;124(4):797\u2013804.","journal-title":"Br J Cancer"},{"issue":"7","key":"13463_CR23","doi-asserted-by":"crossref","first-page":"e180996","DOI":"10.1001\/jamasurg.2018.0996","volume":"153","author":"GA Margonis","year":"2018","unstructured":"Margonis GA, Buettner S, Andreatos N, et al. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg. 2018;153(7):e180996.","journal-title":"JAMA Surg"},{"issue":"9","key":"13463_CR24","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/bjs.11180","volume":"106","author":"JB Bachet","year":"2019","unstructured":"Bachet JB, Moreno-Lopez N, Vigano L, et al. BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases. Br J Surg. 2019;106(9):1237\u201347.","journal-title":"Br J Surg"},{"issue":"9","key":"13463_CR25","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.21873\/anticanres.11040","volume":"36","author":"E Pikoulis","year":"2016","unstructured":"Pikoulis E, Margonis GA, Andreatos N, et al. Prognostic role of BRAF mutations in colorectal cancer liver metastases. AR. 2016;36(9):4805\u201312.","journal-title":"AR."},{"key":"13463_CR26","doi-asserted-by":"crossref","first-page":"v225","DOI":"10.1093\/annonc\/mdz246.076","volume":"30","author":"S Kobayashi","year":"2019","unstructured":"Kobayashi S, Takahashi S, Kojima M, et al. Clinical impact of BRAF V600E mutations in patients (Pts) with resectable solitary colorectal liver metastases (CRLM). Ann Oncol. 2019;30:v225\u20136.","journal-title":"Ann Oncol"},{"issue":"3","key":"13463_CR27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.6004\/jnccn.2020.7619","volume":"19","author":"J Uhlig","year":"2021","unstructured":"Uhlig J, Cecchini M, Sheth A, Stein S, Lacy J, Kim HS. Microsatellite instability and KRAS mutation in stage IV colorectal cancer: prevalence, geographic discrepancies, and outcomes from the national cancer database. J Natl Compr Canc Netw. 2021;19(3):307\u201318.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"13463_CR28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.21873\/anticanres.11313","volume":"37","author":"K Fujiyoshi","year":"2017","unstructured":"Fujiyoshi K, Yamamoto G, Takenoya T, et al. Metastatic pattern of stage IV colorectal cancer with high-frequency microsatellite instability as a prognostic factor. Anticancer Res. 2017;37(1):239\u201347.","journal-title":"Anticancer Res"},{"issue":"4","key":"13463_CR29","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/jso.26352","volume":"123","author":"C Kamphues","year":"2021","unstructured":"Kamphues C, Kadowaki S, Amini N, et al. The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: an international, multi-institutional study in patients with known KRAS, BRAF, and MSI status. J Surg Oncol. 2021;123(4):1005\u201314.","journal-title":"J Surg Oncol"},{"issue":"4","key":"13463_CR30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/jhbp.1054","volume":"29","author":"N Amini","year":"2022","unstructured":"Amini N, Andreatos N, Margonis GA, et al. Mutant KRAS as a prognostic biomarker after hepatectomy for rectal cancer metastases: does the primary disease site matter? J Hepato Biliary Pancreat. 2022;29(4):417\u201327.","journal-title":"J Hepato Biliary Pancreat"},{"issue":"12","key":"13463_CR31","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.6004\/jnccn.2017.7011","volume":"15","author":"ME Charlton","year":"2017","unstructured":"Charlton ME, Kahl AR, Greenbaum AA, et al. KRAS testing, tumor location, and survival in patients with stage IV colorectal cancer: SEER 2010\u20132013. J Natl Compr Canc Netw. 2017;15(12):1484\u201393.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"13463_CR32","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/j.clcc.2019.12.001","volume":"19","author":"P Cavallaro","year":"2020","unstructured":"Cavallaro P, Bordeianou L, Stafford C, et al. Impact of single-organ metastasis to the liver or lung and genetic mutation status on prognosis in stage IV colorectal cancer. Clin Colorectal Cancer. 2020;19(1):e8\u201317.","journal-title":"Clin Colorectal Cancer"},{"issue":"9","key":"13463_CR33","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/s41379-020-0560-x","volume":"33","author":"LA Favazza","year":"2020","unstructured":"Favazza LA, Parseghian CM, Kaya C, et al. KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy. Mod Pathol. 2020;33(9):1832\u201343.","journal-title":"Mod Pathol"},{"issue":"9","key":"13463_CR34","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2217\/bmm-2016-0358","volume":"11","author":"G Kafatos","year":"2017","unstructured":"Kafatos G, Niepel D, Lowe K, et al. RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data. Biomark Med. 2017;11(9):751\u201360.","journal-title":"Biomark Med"},{"issue":"20","key":"13463_CR35","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","volume":"20","author":"S Venderbosch","year":"2014","unstructured":"Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20(20):5322\u201330.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"13463_CR36","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-11-1570","volume":"17","author":"R Sanz-Pamplona","year":"2011","unstructured":"Sanz-Pamplona R, Cordero D, Berenguer A, et al. Gene expression differences between colon and rectum tumors. Clin Cancer Res. 2011;17(23):7303\u201312.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"13463_CR37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/SLA.0000000000002899","volume":"268","author":"MA Schneider","year":"2018","unstructured":"Schneider MA, Eden J, Pache B, et al. Mutations of RAS\/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg. 2018;268(5):845\u201353.","journal-title":"Ann Surg"},{"issue":"7","key":"13463_CR38","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1002\/cam4.2205","volume":"8","author":"K\u00d8 Aaseb\u00f8","year":"2019","unstructured":"Aaseb\u00f8 K\u00d8, Dragomir A, Sundstr\u00f6m M, et al. Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: a population-based cohort of metastatic colorectal cancer patients. Cancer Med. 2019;8(7):3623\u201335.","journal-title":"Cancer Med"},{"issue":"13","key":"13463_CR39","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1245\/s10434-020-08733-x","volume":"27","author":"SK Sherman","year":"2020","unstructured":"Sherman SK, Schuitevoerder D, Chan CHF, Turaga KK. Metastatic colorectal cancers with mismatch repair deficiency result in worse survival regardless of peritoneal metastases. Ann Surg Oncol. 2020;27(13):5074\u201383.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"13463_CR40","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41416-021-01620-6","volume":"126","author":"SG Larsen","year":"2022","unstructured":"Larsen SG, Goscinski MA, Dueland S, et al. Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. Br J Cancer. 2022;126(5):726\u201335.","journal-title":"Br J Cancer"},{"issue":"13","key":"13463_CR41","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753\u20138.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"13463_CR42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5306\/wjco.v11.i6.397","volume":"11","author":"G Fiorentini","year":"2020","unstructured":"Fiorentini G, Sarti D, Patriti A, et al. Immune response activation following hyperthermic intraperitoneal chemotherapy for peritoneal metastases: a pilot study. World J Clin Oncol. 2020;11(6):397\u2013404.","journal-title":"World J Clin Oncol"},{"issue":"9","key":"13463_CR43","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182\u201391.","journal-title":"Lancet Oncol"},{"issue":"10","key":"13463_CR44","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41416-019-0599-y","volume":"121","author":"IH Sahin","year":"2019","unstructured":"Sahin IH, Akce M, Alese O, et al. Immune checkpoint inhibitors for the treatment of MSI-H\/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019;121(10):809\u201318.","journal-title":"Br J Cancer"},{"issue":"49","key":"13463_CR45","doi-asserted-by":"crossref","first-page":"86356","DOI":"10.18632\/oncotarget.21169","volume":"8","author":"ME Salem","year":"2017","unstructured":"Salem ME, Weinberg BA, Xiu J, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017;8(49):86356\u201368.","journal-title":"Oncotarget"},{"issue":"7407","key":"13463_CR46","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"DM Muzny","year":"2012","unstructured":"Muzny DM, Bainbridge MN, Chang K, et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330\u20137.","journal-title":"Nature"},{"issue":"2","key":"13463_CR47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1200\/JCO.21.02014","volume":"40","author":"M Pan","year":"2022","unstructured":"Pan M, Jiang C, Tse P, et al. TP53 gain-of-function and non\u2013gain-of-function mutations are differentially associated with sidedness-dependent prognosis in metastatic colorectal cancer. JCO. 2022;40(2):171\u20139.","journal-title":"JCO"},{"issue":"5","key":"13463_CR48","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3748\/wjg.v24.i5.631","volume":"24","author":"AJ Li","year":"2018","unstructured":"Li AJ, Li HG, Tang EJ, et al. PIK3CA and TP53 mutations predict overall survival of stage II\/III colorectal cancer patients. World J Gastroenterol. 2018;24(5):631\u201340.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"13463_CR49","doi-asserted-by":"crossref","first-page":"100874","DOI":"10.1016\/j.tranon.2020.100874","volume":"13","author":"Q Luo","year":"2020","unstructured":"Luo Q, Chen D, Fan X, Fu X, Ma T, Chen D. KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: a single-site report. Transl Oncol. 2020;13(12):100874.","journal-title":"Transl Oncol"},{"issue":"1","key":"13463_CR50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12876-021-01864-9","volume":"21","author":"T Fang","year":"2021","unstructured":"Fang T, Liang T, Wang Y, et al. Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2021;21(1):297.","journal-title":"BMC Gastroenterol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13463-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13463-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13463-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T13:12:45Z","timestamp":1686229965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13463-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["13463"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13463-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"assertion":[{"value":"10 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}